Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis — ITT-PMS  

Progressive Multiple Sclerosis Clinical Trial

Official title: Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis

Status Completed

Clinical Trial Summary

This is a is a small scale open phase two interventional study to assess long-term stabilising effects of on neurological symptoms by regular intrathecal administered monoclonal antibodies in progressive multiple sclerosis.

Clinical Trial Description

There is presently no efficient therapy available in progressive MS, especially if there is no clear evidence of active inflammatory lesions or exacerbations as part of the disease. There are, however, evidence that some treatment protocols using cytotoxic drugs may to some extent slow down the progressive course. One specific feature of long-standing MS is that inflammatory cells accumulate in the central nervous system(CNS) compartment in the subarachnoid and perivascular spaces and may therefore be hard to reach via standard drug delivery through systemic administration. Administration of substances via the Intrathecal (IT) route, however, have shown to efficiently distribute in the subarachnoid spaces and may therefore be an attractive route of drug delivery ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Sclerosis
• Progressive Multiple Sclerosis
• Sclerosis

• NCT number: NCT01719159
• Study type: Interventional
• Source: Umeå University
• Status: Completed
• Phase: Phase 2
• Start date: November 2009
• Completion date: June 2016